Site search

Clear filter
2898 results for '' found
RATIONALISE - Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (TRU-RLS-21) (ACTRN12622000359730)
RATIONALISE - Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (TRU-RLS-21) (ACTRN12622000359730)
/
A multi-centre, pRospective, safety and efficacy evaluation study on Automated external defibrillation in PatIents with CellAED (ACTRN12621000258853)
/
A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantatio
A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantatio
/
A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma (NCT05608291)
/
A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672)
/
Assessing Benefits of Near Infrared Autofluorescence Detection for Identifying Parathyroid Glands during Endocrine Surgery (NCT05022667)
Assessing Benefits of Near Infrared Autofluorescence Detection for Identifying Parathyroid Glands during Endocrine Surgery (NCT05022667)
/
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (PTG-300-11) (NCT05210790)
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (PTG-300-11) (NCT05210790)
/
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Par
/
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies (NCT05665530)
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies (NCT05665530)
/
PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES [RAINBOW TRIAL] (NCT06371417)
/
24 25 26 27 28